Qian Y, Li S, Ye S, Chen Y, Zhai Z, Chen K, Yang G
Department of Endocrinology, Anhui Provincial Hospital, Hefei, China.
J Endocrinol Invest. 2008 Dec;31(12):1069-74. doi: 10.1007/BF03345654.
To observe the effect of rosiglitazone on serum intercellular adhesion molecule-1 (SICAM-1) level, urinary excretion of ICAM-1, and renal expression of ICAM-1, and investigate its possible renoprotective mechanisms in diabetic rats.
Twenty-four Wistar Rats were divided into 3 groups: non-diabetic control rats (group A, no.=8), streptozotocin-induced diabetic rats (group B, no.=8), and diabetic rats treated with rosiglitazone (group C, no.=8). Rats in group C were treated with rosiglitazone (5 mg x kg(-1) x d(-1)) 1 week after the establishment of diabetic model, group A and B were treated with corresponding sodium chloride. Peripheral blood glucose was tested weekly. Glycosylated hemoglobin (HbA1c) and SICAM-1 as well as urinary albumin excretion rate (UAER), urinary retinol binding-protein (URBP) excretion rate, and urinary ICAM-1 (UICAM- 1) excretion rate were tested at the 8th week, and the renal tissues of all rats were obtained for evaluating kidney/body weight ratio, observing pathologic change via electron microscope, and for examining the expression of ICAM-1 mRNA by reverse transcriptase-PCR.
At the 8th week, the blood glucose, HbA1c levels, UAER, URBP excretion rate, kidney/body weight ratio and serum, urinary ICAM-1 levels all increased significantly in group B and group C in comparison with group A; however, the above-mentioned parameters in group C (except the blood glucose and HbA1c levels) were much lower than those in group B. In addition, both SICAM-1 and UICAM-1 were highly correlated with the UAER, URBP level, and kidney/body weight ratio in all rats; renal pathological lesions observed by electron microscope in group C were much lighter than those of group B; compared with group A, the expression of ICAM-1 mRNA was markedly up-regulated in group B and group C, and rosiglitazone was able to decrease the expression of ICAM-1 mRNA in the renal tissue.
Rosiglitazone could definitely protect against the renal injury of diabetic rats, which may be partly associated with decreasing the expression of ICAM-1 in the renal tissue, reducing ICAM-1 productions in both serum and urine.
观察罗格列酮对糖尿病大鼠血清细胞间黏附分子-1（SICAM-1）水平、ICAM-1尿排泄量及肾脏ICAM-1表达的影响，并探讨其可能的肾脏保护机制。
将24只Wistar大鼠分为3组：非糖尿病对照大鼠（A组，n = 8）、链脲佐菌素诱导的糖尿病大鼠（B组，n = 8）和罗格列酮治疗的糖尿病大鼠（C组，n = 8）。C组大鼠在糖尿病模型建立1周后用罗格列酮（5 mg·kg⁻¹·d⁻¹）治疗，A组和B组用相应的氯化钠治疗。每周检测外周血糖。在第8周检测糖化血红蛋白（HbA1c）和SICAM-1以及尿白蛋白排泄率（UAER）、尿视黄醇结合蛋白（URBP）排泄率和尿ICAM-1（UICAM-1）排泄率，获取所有大鼠的肾脏组织以评估肾重/体重比，通过电子显微镜观察病理变化，并通过逆转录聚合酶链反应检测ICAM-1 mRNA的表达。
在第8周时，与A组相比，B组和C组的血糖、HbA1c水平、UAER、URBP排泄率、肾重/体重比以及血清和尿ICAM-1水平均显著升高；然而，C组的上述参数（血糖和HbA1c水平除外）远低于B组。此外，在所有大鼠中，SICAM-1和UICAM-1均与UAER、URBP水平及肾重/体重比高度相关；C组电子显微镜观察到的肾脏病理损伤比B组轻得多；与A组相比，B组和C组ICAM-1 mRNA的表达明显上调，而罗格列酮能够降低肾脏组织中ICAM-1 mRNA的表达。
罗格列酮确实可以预防糖尿病大鼠的肾脏损伤，这可能部分与降低肾脏组织中ICAM-1的表达、减少血清和尿液中ICAM-1的生成有关。
